NCT05974332

Oncostatin M in Ulcerative Colitis Patients

Serum Oncostatin M in Ulcerative Colitis Patients and Its Relation to Severity and Acute Exacerbation

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 99 (estimated)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

Ulcerative colitis (UC) is a refractory disease characterized by symptoms such as diarrhea, bloody stools, and abdominal pain with repeated relapses and remissions.

Detailed description

Evaluation of UC activity is important, and endoscopic evaluations of mucosal inflammation can facilitate subsequent prognostication. On the basis of these considerations, achievement of mucosal healing is important in inflammatory bowel disease (IBD), and evaluation of IBD using endoscopy is extremely important. However, endoscopic examinations are associated with problems such as physical burden to the patient, cost, and risk of complications. Thus, to avoid the need for frequent endoscopy, noninvasive biomarkers that accurately reflect the endoscopic activity of UC have emerged, and fecal calprotectin (FC) and the fecal immunochemical occult blood test (FIT) are being widely used in clinical practice.

Conditions

• Ulcerative Colitis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Oncostatin M	Test to diagnosis of Ulcerative colitis

Timeline

• Start date: 2023-08-01
• Primary completion: 2024-02-28
• Completion: 2024-03-01
• First posted: 2023-08-03
• Last updated: 2023-08-03